UNASSIGNED: 6068 Background: This study assessed willingness to pay (WTP) to avoid chemotherapy induced @entity1209 (CINV) among 303 @entity5 @entity1 . METHODS: WTP was assessed using results from a conjoint survey. @entity1 viewed 25 scenarios each involving 2 descriptions of CINV and indicated which they preferred. Each scenario represented a combination of levels from 8 CINV related attributes. Importance scores assessing attribute contribution to selection and WTP values were calculated using preference coefficients from a series of probit models. RESULTS: @entity1 were 79% Caucasian and 16% African American. Mean age was 59.4 years (range=26-86). 40% had @entity0 , 35% @entity2 , and 25% @entity14 . 68% were on HEC/ @entity17469 , 22% had been on HEC/ @entity17469 in the last 6 months, and 10% were chemotherapy na  ve. Important scores for attributes were cost: 0.21, chance @entity390 : 0.07, length @entity390 : 0.15, severity @entity390 : 0.16, chance @entity391 : 0.18, and dehydration: 0.15, indicating cost was the strongest driver of @entity1 choice and choice was driven more by a desire to avoid @entity390 than @entity391 . @entity1 were willing to pay to avoid > 30% chance of @entity390 (WTP to avoid 50%:  42.61; WTP to avoid 70%:  49.57), > 1 day of @entity390 (2-5 days:  62.80; 5+ days:  107.50), @entity391 > 1-2 times/day (3-5 times/day:  45.52; 5+ times/day:  52.10), and @entity391 longer than a half-day (1 day:  20.12; 2-5 days:  133.05) with p-values from 0.0004 to <.0001. @entity1 with income  40,000+ were willing to pay more than others to avoid more than 1 day of @entity390 (2-5 days: difference= 93.23; 5+ days: difference= 107.43) and @entity390 that impaired self-care ( 42.62) with p-values from 0.01 to <0.0001. @entity0 @entity1 were willing to pay less to avoid a 25% chance of @entity391 versus lung (difference= 49.95; p=0.0083) and @entity14 @entity1 (difference= 50.80; p=0.0166), respectively. WTP also varied by disease stage, ECOG performance status, HEC/ @entity17469 group, and whether @entity1 had worked while on chemotherapy. CONCLUSIONS: The study identifies a significant WTP to avoid @entity1209 and substantial group differences in WTP that could be incorporated into the management of CINV.

Willingness to pay to prevent chemotherapy-induced XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity0 :: ('MESH:D001943', 'Disease') :: ['Breast cancer', 'breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity17469 :: ('56477', 'Gene') :: ['MEC'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting: 0.02, frequency vomiting: 0.07, length vomiting', 'vomiting'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity1209 :: ('MESH:D020250', 'Disease') :: ['nausea and vomiting']
@entity1209 :: (MESH:D020250,Disease) :: ['nausea and vomiting']
